Athena Athena

X
[{"orgOrder":0,"company":"Sera Labs","sponsor":"CURE Pharmaceutical","pharmaFlowCategory":"D","amount":"$44.0 million","upfrontCash":"$20.0 million","newsHeadline":"CURE Pharmaceutical to Acquire Sera Labs in a $20 Million Transaction","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Sera Labs

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Acquisition of Sera Labs will add to CURE a growing brand portfolio and monetization platform that fits remarkably well with CURE’s development capabilities, products, and existing market verticals.

            Lead Product(s): Cannabidiol,Aspartame

            Therapeutic Area: Dermatology Product Name: Seratopical

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: CURE Pharmaceutical

            Deal Size: $44.0 million Upfront Cash: $20.0 million

            Deal Type: Acquisition July 28, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY